Physician profile
Mohammad Masroor
NPI 1306994157
$2,889.90
in general payments reported to CMS, 2019-2025
19 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $204 · 2021: $526 · 2022: $632 · 2023: $455 · 2024: $419 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $592.91 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $414.81 | 2019-2025 | Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $402.78 | 2021-2025 | Verquvo, Steglatro |
| Amgen INC. | $379.71 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $139.77 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $133.82 | 2019-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $126.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.39 | 2021-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $87.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $86.16 | 2019-2024 | Xarelto |
| Pfizer INC. | $82.04 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.76 | 2025 | |
| Baxter Healthcare | $63.99 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $60.39 | 2023-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $46.80 | 2023-2024 | Inpefa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.99 | 2021 | |
| Novo Nordisk INC | $17.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2019 | |
| Abbott Laboratories | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Masroor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.